updates on management of adolescent pcos an evidence based approach
TRANSCRIPT
Updates on management of
Adolescent PCOS An evidence based approach
Aboubakr Elnashar Benha university, Egypt
ABOUBAKR ELNASHAR
GUIDELINES
In 2012:
ESHRE/ASRM-sponsored 3rd PCOS
In 2013
Endocrine Society Clinical Practice
In 2015
1. Androgen Excess PCOS Society, Pediatric
endocrine Society
2. Italian society of endocrinology
3. American Association of Clinical
Endocrinologists (AACE) and the Androgen
Excess and PCOS Society (AES)
ABOUBAKR ELNASHAR
CONTENTS
1.Diagnosis
2.Evaluation
3.Treatment
Conclusion
ABOUBAKR ELNASHAR
Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) Endocrine Society Clinical Practice (2013)
Strength of the recommendation
strong recommendations use the phrase “we
recommend” and the number 1
weak recommendations use the phrase “we
suggest” and the number 2.
Quality of the evidence, Cross-filled circles
+OOO: very low quality evidence
++OO: low quality
+++O: moderate quality
++++: high quality. ABOUBAKR ELNASHAR
1. DIAGNOSIS Androgen Excess PCOS Society, Pediatric endocrine society(2015)
Great caution
before diagnosis with clinical features of androgen
excess (hirsutism and biochemical hyperandrogenism) if
oligomenorrhea has not persisted for ≥2 ys.
These girls can be considered to be at risk for
PCOS.
{avoid misdiagnosing physiological pubertal changes as
PCOS}
Postpone diagnosis
Frequent longitudinal re-evaluations (Level C).
ABOUBAKR ELNASHAR
ESHRE/ASRM (2012)
All 3 elements of the Rotterdam criteria should be
present Oligomenorrhea or amenorrhea:
should be present for at least 2 ys after menarche or
primary amenorrhea at age 16 ys
US Diagnosis of PCO:
should include increased ovarian size (>10 cm3) {multifollicular ovaries are a feature of normal puberty that subsides with onset of regular menstrual cycling and may be difficult to distinguish from PCO morphology }
Hyperandrogenemia:
rather than just signs of androgen excess should be
documented.
ABOUBAKR ELNASHAR
Endocrine Society Clinical Practice (2013)
For diagnosis:
Clinical and/or biochemical evidence of
hyperandrogenism (after exclusion of other
pathologies) plus
Persistent oligomenorrhea
Anovulatory symptoms and PCO morphology:
not sufficient to make a diagnosis
{±evident in normal stages in reproductive
maturation} (2++OO).
ABOUBAKR ELNASHAR
Hyperandrogenemia
Extremely important
No established normal ranges.
FT ≥ 1.3 ng/dL, (Piltonen et al, 2005)
TT >1 µg/ml (The Rotterdam consensus workshop group, 2004).
Adult cutoffs should be used until appropriate
pubertal levels are defined. (Endocrine Society Clinical Practice , 2013)
ABOUBAKR ELNASHAR
AMH:
elevated AMH may serve as a noninvasive
screening or diagnostic test for PCO,
although there are no well-defined cutoffs (Pawelczak et al, 2012; Rosenfield et al, 2012).
ABOUBAKR ELNASHAR
2. EVALUATION 1. Cutaneous manifestations
Physical examination should document cutaneous
manifestations of PCOS: Terminal hair growth
Acne
Alopecia,
Acanthosis nigricans
Skin tags (1+++O).
(Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
2. Obesity
{Increased adiposity, particularly abdominal, is associated
with hyperandrogenemia and increased metabolic risk }
Screening for increased adiposity, by
BMI calculation
measurement of waist circumference (1+++O).
(Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
3. Depression
screening for depression and anxiety by
history and,
if identified: referral and/or treatment (2++OO).
(Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
4. Sleep-disordered breathing/obstructive sleep
apnea (OSA)
screening overweight/obese adolescents for symptoms suggestive of OSA when identified: definitive diagnosis using polysomnography: referred for treatment (2++OO). (Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
5. Type 2 diabetes mellitus (T2DM)
OGTT to screen for IGT and T2DM
{they are at high risk for such abnormalities} (1+++O).
HgbA1c test if a patient is unable or unwilling to
complete an OGTT (2++OO).
Rescreening:
/3–5 y
more frequently if:
central adiposity
substantial weight gain, and/or
symptoms of diabetes develop (2++OO).
(Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
6. Cardiovascular risk
screened for the following CVD risk factors: family history of early CVD cigarette smoking, IGT/T2DM hypertension, dyslipidemia, OSA, and obesity (especially increased abdominal adiposity) (1++OO). (Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
3. TREATMENT Indications
Even in the absence of a definitive diagnosis:
treatment that
alleviate symptoms
decrease the risk for subsequent associated
comorbidities are recommended (Level B).
(Androgen Excess PCOS Society; Pediatric endocrine society, 2015)
Individual PCOS manifestations: obesity, hirsutism,
irregular menses should be treated. (level B)
(ESHRE/ASRM; 2012)
ABOUBAKR ELNASHAR
Lines of therapy
1. lifestyle therapy:
First-line strategy
Weight loss
Calorie-restricted diets (with no evidence that
one type of diet is superior) (2++OO).
Beneficial for both reproductive and metabolic
dysfunction. (Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
Exercise
use of exercise therapy in the management of
overweight and obesity in PCOS (2++OO).
{ improves weight loss reduces CV risk factors and diabetes risk}. (Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
2. Hormonal contraceptives (HCs):
Indications:
First-line management for the
menstrual abnormalities
hirsutism/acne (1++OO).
(Endocrine Society Clinical Practice, 2013)
ABOUBAKR ELNASHAR
Types:
oral contraceptives, patch, or vaginal ring
do not suggest one HC formulation over another (2++OO).
OCPs either containing or not containing an
antiandrogen (Italian society of endocrinology, 2015)
ABOUBAKR ELNASHAR
Metabolic effects of COC containing 30ug or less
of EE: mild Deterioration of glucose tolerance
Worsening of lipid profile
should not influence the choice (Italian society of endocrinology, 2015)
ABOUBAKR ELNASHAR
VTE risk is not studied
Odds ratio
1.65 for BMI 25–30 kg/m2
1.84 for BMI 30–35 kg/m2
4.34 for BMI >35 kg/m2 [Murthy, 2010].
risk is further increased in CPA or 3rd generation
progestins, including drospirenone [Lenzer, 2011].
ABOUBAKR ELNASHAR
Screening for contraindications
via established criteria (1+++O).
lipid profile and the glucose tolerance should be
evaluated before and after 3 months of higher dose
OC containing cyproterone acetate (Italian society of endocrinology, 2015)
ABOUBAKR ELNASHAR
BMI: ≤35 kg/m2 with no specific metabolic and/
or CV abnormalities
choose from various OC formulations, acc to the
preferences of the physician and patient, and the
specific clinical characteristics of the patient. (Italian society of endocrinology, 2015)
BMI
≥35 kg/m2 : OC should be prescribed with caution
≥40 kg/m2: not used (RCOG, 2011). If contraception is needed, alternative measures should be preferred, such as progestin-only methods. (Italian society of endocrinology, 2015)
ABOUBAKR ELNASHAR
3. Metformin:
Indications
if the goal is to treat IGT/metabolic syndrome (2++OO).
who wish for long-term resumption of ovulation,
especially those with metabolic alterations with an
inadequate response to lifestyle intervention
ABOUBAKR ELNASHAR
Met and COC have comparable therapeutic
effectiveness on cycle regularity and hirsutism.
Met was associated with a sig improvement in
insulin sensitivity
COC was associated with a deterioration of
insulin sensitivity
ABOUBAKR ELNASHAR
4. Combined metformin and OC
:
attenuating the adverse metabolic effects of OC
improving body composition
, as compared with OC alone [Glintborg et al, 2014].
ABOUBAKR ELNASHAR
Duration of HC or metformin
Not yet been determined.
OCPs should be continued until the patient is
gynecologically mature (5y postmenarcheal) or
has lost a substantial amount of excess weight. (Rosenfield; 2015)
ABOUBAKR ELNASHAR
CONCLUSIONS
Diagnosis:
Criteria for the diagnosis differ from those used for
older women of reproductive age
Hyperandrogenaemia: the most consistent marker
Early diagnosis for timely initiation of therapy,
outweighs harms and burdens of misdiagnosis.
ABOUBAKR ELNASHAR
Evaluation:
metabolic and CV risks,
psychologic and dermatologic .
Treatment
should be individualized depending on
Age
Stage in life
Symptoms
Personal and familial risk indices
Choices.
ABOUBAKR ELNASHAR
ABOUBAKR ELNASHAR
My scientific page on
Slideshare
260 lectures
3192 members